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ABSTRACT 
Clinical history, questionnaire data and response to antisecretory therapy are insufficient to make a 
conclusive diagnosis of GERD in isolation, but are of value in determining need for further investigation. 
Conclusive evidence for reflux on esophageal testing include advanced grade erosive esophagitis (LA 
grades C and D), long-segment Barrett’s mucosa or peptic strictures on endoscopy, or distal esophageal 
acid exposure time (AET) >6% on ambulatory pH or pH-impedance monitoring. A normal endoscopy 
does not exclude GERD, but provides supportive evidence refuting GERD in conjunction with distal AET 
<4% and <40 reflux episodes on pH-impedance monitoring off PPI. Reflux-symptom association on 
ambulatory reflux monitoring provides supportive evidence for reflux triggered symptoms, and may 
predict a better treatment outcome when present. When endoscopy and pH- or pH-impedance monitoring 
are inconclusive, adjunctive evidence from biopsy findings (histopathology scores, dilated intercellular 
spaces), motor evaluation (hypotensive lower esophageal sphincter, hiatus hernia and esophageal body 
hypomotility on high-resolution manometry) and novel impedance metrics (baseline impedance, post-
reflux swallow induced peristaltic wave index) can add confidence for a GERD diagnosis; however, 
diagnosis cannot be based on these findings alone. An assessment of anatomy, motor function, reflux 
burden and symptomatic phenotype will therefore help direct management. Future GERD management 
strategies should focus on defining individual patient phenotypes based on the level of refluxate exposure, 
mechanism of reflux, efficacy of clearance, underlying anatomy of the esophagogastric junction, and 
psychometrics defining symptomatic presentations. 
Keywords: gastroesophageal reflux disease; pH-impedance monitoring; manometry; endoscopy 
  
Gyawali et al 4 
 
INTRODUCTION 
Gastroesophageal reflux disease (GERD) has an estimated worldwide prevalence of 8-33%, 
involves all age groups and both genders
1
, and carries a price tag estimated at >$9-10 billion/year in the 
US alone, largely related to proton pump inhibitors (PPI) use and diagnostic testing
2
. The current 
paradigm of GERD diagnosis hinges on the identification of esophageal mucosal lesions or troublesome 
symptoms caused by gastroesophageal reflux
3
. A putative GERD diagnosis is bolstered by a favorable 
response to PPI therapy
4
. The primary determinant of mucosal injury is excessive esophageal acid 
exposure attributable to anatomical or physiological defects of the esophagogastric junction (EGJ) and 
esophageal peristalsis
5
. GERD symptoms, however, have multiple potential determinants including the 
number of reflux episodes, the proximal extent to which the refluxate migrates, the acidity of the 
refluxate, esophageal hypersensitivity, and cognitive hypervigilance. Consequently, depending on the 
clinical context, the defining features of GERD can be pathology, physiology, or symptomatology. In this 
paradigm, esophageal testing is often undertaken to define optimal management, be that PPI therapy, 
antireflux surgery (ARS), or cognitive behavioral therapy.  
The aim of the GERD consensus process was to determine modern indications for esophageal 
testing in GERD, and as an extension to that aim, to define criteria for a clinical diagnosis of GERD. The 
consensus process started in 2014, when the primary aims were formulated, followed by a literature 
search and grading of evidence. There was extensive discourse within a multi-national group of GERD 
experts over 2 years, following which consensus statements were developed and published
6-8
.  These 
consensus statements were adapted for the practicing gastroenterologist by a cohort of international 
experts at the Lyon GERD consensus meeting in November 2017, the conclusions from which are 
presented in this manuscript. 
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DIAGNOSIS OF GERD 
GERD is empirically diagnosed and treated in clinical practice based on the clinician’s symptom 
assessment. Indications for testing include treatment failure, diagnostic uncertainty, and treating (or 
preventing) complications of GERD. However, diagnostic testing may or may not support the initial 
diagnosis, as the criteria defining GERD are specific to each testing modality. Consequently, 
understanding the performance characteristics of each diagnostic modality and recognizing evidence that 
supports or refutes the clinical impression of GERD is crucial. The Lyon Consensus evaluated GERD 
diagnostic tests from that perspective, and test results were categorized as being adequate to establish or 
refute a GERD diagnosis or inconclusive in the absence of additional supportive evidence. 
The primary focus of esophageal testing has hitherto been restricted to detection of excessive acid 
reflux as indicative of pathologic GERD, supported by reflux-symptom association analysis. The 
threshold value discriminating abnormal from normal esophageal acid exposure with 24-hour pH-metry 
was initially selected based on evidence that higher acid exposure is associated with the presence of reflux 
esophagitis
9
. However, the focus of current GERD management is not only on healing mucosal disease 
but also on managing symptoms. The association of esophageal acid exposure with patient symptoms is 
weak
10, 11
, making sole reliance of this metric problematic. Expansion of testing to include esophageal 
mucosal impedance, manometry, histopathology, and psychometrics may help in this regard, potentially 
identifying distinct GERD phenotypes with unique management implications. Each test adds a piece to 
the overall puzzle of symptom generation, disease pathophysiology, and precision management. 
 
Clinical history and questionnaires 
Typical GERD symptoms (heartburn and acid regurgitation) are more likely than atypical 
symptoms to respond to treatment, emphasizing the value of an accurate clinical history
5
. However, when 
compared to objective evidence of GERD defined by pH-metry or endoscopy, even an expert history by a 
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gastroenterologist has only 70% sensitivity and 67% specificity
12
, reiterating the distinction between a 
physiology-based and a symptom-based GERD diagnosis. Likewise, questionnaires such as the reflux 
disease questionnaire (RDQ) and GERDQ have similar limitations when compared to physiologic 
testing
12-14
. However, in clinical practice, diagnosing and treating GERD based on typical symptoms is 
pragmatic and endorsed by societal guidelines
4
, even though these symptoms are neither sensitive nor 
specific for objectively defined GERD
12
.  
 
Proton pump inhibitor (PPI) trial 
Although pragmatic, symptomatic response to PPI therapy does not equate to a GERD diagnosis, 
exhibiting an imperfect correspondence with objectively defined disease. On average, 69% of esophagitis 
patients, 49% of non-erosive reflux disease (NERD) patients, and 35% of patients with normal endoscopy 
and pH-metry gain symptom relief from a PPI trial
15
. Hence, when evaluated as a diagnostic test for 
GERD among heartburn patients, an empiric PPI trial has a sensitivity of 71% and specificity of only 
44% compared to the combination of endoscopy and pH-metry 
12,16
. With atypical symptoms (chest pain, 
chronic cough, laryngitis, etc), PPI response rates are much lower than with heartburn, thereby 
diminishing the utility of that approach to diagnosis 
17
. A major limitation of the “PPI test” is the strong 
modulation of symptoms by esophageal hypersensitivity 
18,19
; there is also variation in PPI dosing and 
duration of the test
20
. Nonetheless, despite low specificity and high placebo response
21
, the empiric PPI 
treatment approach is less costly than diagnostic testing
22
 and is endorsed by societal guidelines
4, 23
 
undoubtedly leading to the over-diagnosis of GERD and overuse of PPIs.  
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Endoscopy and biopsy 
When putative GERD symptoms do not respond to empiric PPI therapy, upper endoscopy (EGD) 
is advised both to evaluate for GERD complications and to detect potential alternative diagnoses that 
might redirect therapy. High-grade esophagitis (LA Grades C or D), Barrett’s esophagus, or peptic 
stricturing are considered confirmatory evidence for GERD
6
. However, erosive esophagitis is found in 
only 30% of treatment-naive heartburn patients and in <10% when already taking a PPI.
24, 25
 Furthermore, 
most of that is low-grade, and lower grades of esophagitis, particularly LA Grade A, are nonspecific, 
found in 5-7.5% of asymptomatic controls
26-28
. When accurately defined, LA Grade B esophagitis 
provides adequate evidence for initiation of medical management of GERD, but problems with inter-
observer variability led an expert panel to conclude that additional pH-metry evidence is requisite prior to 
pursuing anti-reflux surgery (ARS)
29
. Barrett’s esophagus is observed in 5-15% of chronic GERD patients 
30-32
, but histological confirmation is documented in only 50% of these. In summary, EGD findings can be 
clinically important and specific for GERD, but EGD has a low sensitivity in GERD diagnosis.  
The Rome IV consensus recommended esophageal biopsies during EGD to rule out eosinophilic 
esophagitis
33
. Biopsies may also have value in differentiating NERD (with positive pH-metry) from reflux 
hypersensitivity, functional heartburn and controls when scored using a structured histopathological 
protocol evaluating papillary elongation, basal cell hyperplasia, dilated intercellular spaces, intraepithelial 
inflammatory cells, necrosis and erosions 
34, 35
; changes that resolve following adequate GERD therapy 
36
. 
However, histopathological findings can overlap between the groups studied, and are not conclusive of 
GERD. Identification of dilated intercellular spaces on electron microscopy suggests mucosal injury from 
reflux
37, 38
, but clinical application is limited. The widespread adoption of histopathological examination 
for GERD injury is hindered by the cumbersome protocol and need for a dedicated esophageal 
pathologist
34, 39, 40
.  
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Ambulatory reflux monitoring 
Ambulatory reflux monitoring can provide confirmatory evidence of GERD, in patients with 
normal endoscopy, atypical symptoms and/or when contemplating ARS 
6
. Reflux monitoring 
demonstrates the consequence of GERD pathophysiology, evident as either excessive esophageal acid 
exposure time (AET) or reflux episodes, rather than the mechanism by which that occurs. Reflux-
symptom association utilizes simple ratios and statistical tests to determine whether reflux episodes co-
occur with symptoms, and adds value to ambulatory reflux monitoring. Hence, reflux monitoring can 
confirm or exclude pathologic GERD, albeit not always conclusively.  
The primary outcome of a 24-hour pH-metry study is the AET. Extending recording time to 48 or 
96 hours with the wireless pH monitoring system increases the diagnostic yield 
41-43
 and test 
reproducibility
44
, and is particularly useful when a transnasal catheter was not tolerated or yielded a 
negative result despite high suspicion of GERD
41, 45
. However, wireless pH monitoring is expensive, 
limiting its availability. Another variation on reflux monitoring is pH-impedance monitoring, which 
characterizes reflux events with both a pH electrode and a series of impedance electrodes. Since pH-
impedance detects all reflux (liquid, gas or mixed) regardless of acidity, and defines the direction of flow, 
it is considered the gold standard 
6, 46
. However, the added yield is limited 
47, 48
, the test is not widely 
available, and the interpretation is laborious. 
Reflux monitoring can be done ‘on’ or ‘off’ PPI therapy in patients with persistent and/or atypical 
symptoms despite PPI therapy. The Lyon Consensus proposes that testing always be performed off 
therapy to demonstrate baseline AET in ‘unproven GERD’, meaning no (or low grade) esophagitis at 
endoscopy, and no prior positive pH testing
8
. Testing off therapy is also recommended when done to 
evaluate for ARS 
6, 33
. In contrast, the Lyon Consensus proposes that patients with ‘proven GERD’ (prior 
LA Grade C or D esophagitis, long segment Barrett’s esophagus, or prior abnormal pH-metry) be 
evaluated on double-dose PPI therapy to establish correlation between refractory symptoms and reflux 
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episodes and/or to exclude inadequate acid suppression or poor compliance as the mechanism of 
persisting symptoms. This assessment requires pH-impedance (versus pH) monitoring since most reflux 
episodes on PPI therapy are weakly acidic (pH 4-7) 
49, 50
. 
Assessment of proximal esophageal or pharyngeal reflux has also been proposed, but 
methodology and interpretation have not been standardized, and outcome studies are currently lacking 
51-
54
. An additional problem with the pharyngeal pH probe designed to evaluate both aerosolized and liquid 
acid reflux 
55
 is that it detects pharyngeal pH drops in the absence of concomitant esophageal pH-
impedance events 
56, 57
, even in post-gastrectomy patients, raising questions about its accuracy 
58
.  
 
Interpretation of pH and pH-Impedance Monitoring 
Among the pH monitoring metrics, AET is the most reproducible
59
, is reliably extracted from 
automated analysis, and is predictive of response from medical and surgical reflux therapy 
60, 61
. However, 
the significance of an abnormal AET is proportionate to the degree of abnormality, and the Lyon 
Consensus proposes that AET less than 4% be considered definitively normal (physiologic) and greater 
than 6% be considered definitively abnormal 
6
 with intermediate values between these limits being 
inconclusive. Another outcome metric of pH-impedance monitoring is the number of reflux episodes 
(acidic, weakly acidic or weakly alkaline) with the caveat that this is overestimated by the automated 
analysis and requires manual review of the tracing
62
. The Lyon GERD Consensus proposes that > 80 
reflux episodes per 24 hours are definitively abnormal, while a number <40 is physiologic 
6
 and 
intermediate values inconclusive. The clinical relevance of an abnormal number of reflux episodes 
remains incompletely defined, although recent preliminary data demonstrate improvement of 
regurgitation verified by increased reflux episodes following magnetic sphincter augmentation
63
. 
Consequently, this is considered an adjunctive measure to be utilized when AET is inconclusive (i.e. 
between 4-6%). pH-impedance monitoring assists diagnosis of belching disorders and rumination, which 
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can mimic reflux disease. Additional impedance parameters such as bolus exposure, baseline impedance 
and post reflux swallow-induced peristaltic wave (PSPW) also have potential as reflux metrics, but 
outcome data are currently limited.  
 
Reflux-Symptom Association 
Both pH monitoring and combined pH-impedance monitoring provide analysis of the temporal 
association between symptoms with a crisp onset (e.g. heartburn, regurgitation, chest pain, cough or 
belching) and reflux episodes 
64
 . The time window applied for reflux-symptom association analysis is 2 
minutes 
65, 66
. The Symptom Index (SI) is the percentage of symptom events preceded by reflux episodes 
67
, and the optimal SI threshold for heartburn is 50% 
68
. The disadvantage of the SI is that the number of 
reflux episodes is not considered leaving open the possibility of chance association. The Symptom 
Association Probability (SAP) and the Ghillebert Probability Estimate (GPE), also known as Binomial 
Symptom Index (BSI), use more complex statistical calculations to express the probability that symptom 
events and reflux episodes are associated 
69, 70
 and are considered positive if the probability (p value) of 
the observed association occurring by chance is < 5%. Both SAP and GPE/BSI take all relevant 
components, i.e. total numbers of symptom events, reflux episodes and reflux-related symptom events, 
into account. In summary, SI is a measure of “effect size”, whereas SAP is a measure of probability. As 
such the two metrics are complementary, measure different things and cannot be compared to each other. 
The combination of a positive SI and positive SAP provides the best evidence of a clinically relevant 
association between reflux episodes and symptoms
6, 71, 72
. Both the SI and SAP are predictive of the effect 
of medical and surgical anti-reflux therapy, independent of AET 
73-76
. 
The reliability of reflux-symptom association analysis is critically dependent on proper execution 
of the reflux monitoring procedure and meticulous analysis protocols including careful selection of 
symptoms of interest. Patients must be instructed to use the symptom event button on the portable data 
logger accurately and to fill in the symptom diary accurately. The outcome of symptom association 
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analysis is more reliable when at least three symptom events occur during the test
6
. When cough is the 
symptom of interest, an automated acoustic or manometric cough monitor is necessary to accurately 
capture cough events
77, 78
. Prolonged wireless pH monitoring increases the yield of symptom association 
analysis 
41, 42
, as does combined pH-impedance monitoring with the detection of weakly acidic reflux 
episodes 
79
. This requires manual analysis, as automated analysis significantly over-detects weakly acidic 
reflux episodes and inaccurately reports association with non-acid reflux events in nearly 20% of cases 
62
. 
However, “rapid” visual analysis limited to the 2-minute window preceding each symptom event yields 
SI and SAP values concordant with a full visual analysis, with excellent intra- and inter-observer 
agreement 
80
. Although pH-impedance monitoring provides analysis of symptom-reflux association on 
PPI therapy, testing off PPI therapy increases the number of symptoms reported, which increases the 
chance of a positive symptom-reflux association 
81
.  
Reflux-symptom association analysis has a high degree of reproducibility, the SI being somewhat 
less reproducible than the SAP 
82
. Monte Carlo simulations have identified limitations of reflux-symptom 
association analysis, especially when acid exposure is low and symptom events are few 
83, 84
. If new 
methods for reflux-symptom association are developed in the future, rigorous outcome testing will be 
needed to define superiority to the existing metrics. 
 
Novel Metrics  
 Two novel impedance-detected parameters, the PSPW index and baseline impedance have been 
investigated within GERD phenotypes
85, 86
. These metrics may augment the diagnostic value of 
impedance-pH testing, especially in discriminating patients with GERD from those with functional 
heartburn
87-89
. In health, reflux episodes trigger primary peristalsis to neutralize acidified esophageal 
mucosa with saliva. This is evident as the antegrade progression of impedance decline within 30 seconds 
of a reflux episode (PSPW) on a pH-impedance study
88
. The PSPW index, which currently requires 
cumbersome manual calculation as it is not programmed into the analysis software, consists of the 
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proportion of reflux episodes on pH-impedance monitoring followed by a PSPW. The PSPW index 
reflects the integrity of primary peristalsis stimulated by reflux episodes, correlates with contraction 
reserve assessed using multiple rapid swallows (MRS)
90
, and has excellent performance characteristics in 
differentiating erosive esophagitis and pathological acid exposure from functional heartburn and controls 
(sensitivity 99-100%, specificity 92%)
88, 91
.  
 Baseline impedance values reflect the permeability of the esophageal mucosa, both in animal 
models and healthy volunteers, with lower values found in erosive and non-erosive GERD
92, 93
. Low 
baseline esophageal mucosal impedance has been linked to alteration in intercellular space and tight 
junctions
94, 95
 and to reflux symptoms
96
. Since frequent swallows and reflux events impact measurement, 
baseline impedance is best measured from pH-impedance tracings during sleep, termed mean nocturnal 
baseline impedance (MNBI) when averaged from three 10-minute periods spaced an hour apart
85
. MNBI 
is lower in persisting erosive esophagitis compared to healed esophagitis
97
, in PPI-responsive NERD and 
chronic cough compared to PPI-refractory states
85, 98
, and in erosive esophagitis, NERD and reflux 
hypersensitivity compared to functional heartburn and healthy controls
87,
 
88, 94
. Low MNBI (<2292 ohms) 
independently predicts response to antireflux therapy
99
, links PPI responsive heartburn to reflux better 
than AET
91
, and improves with healing esophagitis
100, 101
. 
Baseline impedance can also be directly measured from the esophageal mucosa. Initially, this was 
done using probes with impedance sensors that were passed through the endoscope.  Subsequently, the 
design has improved using two radial sensors mounted on a 10-cm balloon that is inflated to insure 
optimal contact with a long segment of esophageal mucosa. Baseline mucosal impedance values correlate 
with esophageal mucosal inflammation, differentiating erosive and non-erosive GERD from eosinophilic 
esophagitis and normal patients with better specificity (95% vs. 64%) and positive predictive value (96% 
vs. 40%) compared to pH monitoring.
102-104
 Similar to baseline impedance from pH-impedance 
monitoring, values normalize following PPI therapy. Although normative values are not yet available, 
ongoing studies should clarify the role of mucosal impedance measurements in GERD management. 
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Esophageal high-resolution manometry 
A common indication for high-resolution manometry (HRM) is to accurately place pH or pH-
impedance catheters. HRM is also used to assess peristalsis and to detect alternative major motor 
disorders prior to ARS or when symptoms do not improve with GERD therapy. Consequently, HRM 
studies are often performed in the setting of GERD. Nonetheless, although fundamental to GERD 
pathophysiology, a pathophysiologic classification of motor findings in GERD was only recently 
described
7
. 
 
EGJ Barrier Function 
 The most fundamental abnormality in GERD is incompetence of the EGJ as an antireflux barrier, 
making quantifying EGJ competence an attractive biomarker. However, the EGJ is a complex sphincter 
composed of both the crural diaphragm (CD) and lower esophageal sphincter (LES), the relative 
dominance of which varies with circumstance. Not only does EGJ pressure vary with time, respiration 
and swallowing, but EGJ morphology can also vary over time, transitioning between superimposed and 
separated CD and LES elements
105
. Furthermore, some degree of EGJ incompetence is physiological, 
evident by the phenomenon of transient LES relaxation (TLESR), reflex relaxation of both the LES and 
CD that facilitates gas venting from the stomach
106
. Clearly, there are challenges to quantifying EGJ 
barrier function. 
 No single HRM metric adequately summarizes EGJ competence. Hence, the Lyon Consensus 
proposes adopting two metrics, one expressing the anatomical morphology of the EGJ and the second 
summarizing its contractile vigor. EGJ morphology, defined by the relationship between the LES and CD, 
has been characterized into three subtypes on HRM
107, 108
: type 1 with superimposed LES and CD, type 2 
with axially separated LES and CD pressure signals separated by less than 3 cm, and type 3 with a ≥3 cm 
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separation between the LES and CD pressure signatures (Figure 1). Type 3 EGJ morphology is associated 
with reduced LES pressure and lower inspiratory augmentation, which correlates with reflux severity
107, 
109, 110
. However, this relationship is not linear and there are clear exceptions. 
 The second HRM metric to quantify EGJ barrier function is the EGJ contractile integral (EGJ-CI) 
(Figure 2). The EGJ-CI is calculated using methodology analogous to that for calculating the distal 
contractile integral (DCI) with the DCI box set to encompass the LES and CD over a period of three 
respiratory cycles above a threshold of gastric pressure. The calculated “DCI” is then divided by the 
duration of the three respiratory cycles to make it independent of time and expressed in units of 
mmHg●cm
111
. Several groups of investigators have subsequently tested the performance of the EGJ-CI in 
segregating GERD populations (Table 1)
111-115
, with general agreement that this metric identifies a subset 
of patients with severe barrier dysfunction prone to either endoscopic esophagitis or unequivocally 
abnormal reflux testing. However, it is also evident from the spread of normal ranges reported among 
these studies that there are likely methodological discrepancies in exactly how the EGJ-CI is calculated. 
In view of this, the Lyon Consensus concluded that the EGJ-CI is a promising metric, but needs further 
research before widespread adoption. In an attempt to standardize methodology among groups, they 
recommended exclusion of CD component of the EGJ in instances of type 3 EGJ morphology and 
calculation of EGJ-CI above the gastric baseline pressure. 
 Further insight into the genesis of the EGJ-CI has been gleaned through studies using 3D-
HRM
116
. Isolation of the CD component of the composite EGJ signal on 3D-HRM concluded that 
approximately 85% of overall EGJ contractility was attributable to the CD
117
. Further, analysis of 3D-
HRM recordings differentiating the CD and LES constituents of the EGJ pressure complex demonstrated 
that the CD component correlated strongly with the EGJ-CI, suggesting that both are largely determined 
by CD contractility
118
. Together, these studies provide physiological support for adopting the EGJ-CI as a 
good summary metric of EGJ barrier function, albeit with the caveat that the metric is largely an indicator 
of CD contractility. 
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Esophageal Peristaltic Function 
Esophageal peristalsis can be characterized by the DCI which summarizes the vigor of post 
transition zone contraction (Figure 2) 
108
. A DCI threshold of 450 mmHg●cm●s correlates with an 
averaged distal peristaltic amplitude of 30 mmHg
119
, the original manometric threshold defining 
ineffective swallows. When abnormal, esophageal peristalsis is often weak in GERD 
120-122
, with poor 
and/or delayed formation of post transition zone contraction segment 
123
. This can result in major breaks 
(>5 cm) in the peristaltic contour even when contraction vigor is preserved, a condition termed 
fragmented peristalsis when ≥50% of test swallows demonstrate this finding108.  
Peristaltic dysfunction becomes progressively more common going from NERD to erosive 
esophagitis, to Barrett’s esophagus124, 125. High proportions of ineffective contractions increase the 
likelihood of abnormal AET, particularly while supine 
126
, and increase the likelihood of reflux 
symptoms
127
. The Chicago Classification defines ineffective esophageal motility (IEM) as ≥50% of test 
swallows with DCI<450 mmHg●cm●s, inclusive of any combination of weak (DCI 100-450 
mmHg●cm●vs) or failed (DCI<100 mmHg●cm●s) sequences
108
. Failed sequences are more predictive of 
an abnormal AET than a similar proportion of weak sequences 
128
. The greatest reflux burden is seen with 
absent contractility (100% of test swallows with DCI<100 mmHg●cm●s)
129
. 
 
Provocative Tests 
The physiological phenomenon of deglutitive inhibition is more pronounced with multiple 
swallows in rapid succession such that the esophagus remains in inhibition until after the final swallow, 
which is then followed by a peristaltic contraction 
130
. Multiple rapid swallows (MRS) and rapid drink 
challenge (RDC) are two provocative tests of the integrity of deglutitive inhibition during HRM
131
.  With 
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MRS, five 2-ml swallows are taken less than 4 seconds apart and with RDC 200 ml of water is swallowed 
within 30 seconds. The Lyon Consensus proposes that every HRM study should be accompanied by at 
least one of these provocative tests. 
Post-MRS contractions are an indicator of ‘contraction reserve’ in the esophagus, the 
phenomenon wherein the post-MRS contraction has greater DCI than the preceding test swallows (Figure 
2) 
132
. Recent data suggests three MRS sequences for reliable assessment of contraction reserve
133
. The 
absence of contraction reserve in IEM is predictive of the poor efficacy of promotility drugs 
134
, higher 
AET in NERD 
90
, outlet obstruction and subsequent benefit from dilation following ARS
135
 
136
, and 
persistence or development of IEM after ARS 
137
. Absent contraction reserve is also the most common 
manometric finding in systemic sclerosis.
138
 The Lyon Consensus accepted the value of adopting MRS 
into HRM protocols for determining contraction reserve in IEM or absent contractility 
108
, acknowledging 
that MRS is the most widely studied provocative test 
132, 136, 139
, provides a computationally simple 
endpoint (peristaltic augmentation ratio: post-MRS versus pre-MRS) 
138
, and is quick and easy to 
perform. 
In contrast to MRS, the most important clinical application of RDC is in distinguishing EGJ 
obstruction from achalasia, by identifying LES relaxation in the former, and an exaggerated pressure 
gradient across a non-relaxed EGJ in the latter 
140
 
141, 142
. Therefore, RDC is most helpful in detecting pan-
esophageal pressurization in achalasia, identifying increased resistance to EGJ outflow, and uncovering 
latent hypercontractility 
140
. Additionally, RDC may offer supportive evidence for erosive GERD; 
effective post-RDC peristalsis was seen in 83% of healthy controls compared to 70% of patients with 
NERD and only 30% of patients with erosive esophagitis 
143
. Solid test meals have also been utilized as 
provocative tests during HRM, mainly in evaluating transit symptoms
143-146
. Normal values of esophageal 
pressure responses to RDC and solid meals have been recently reported in normal healthy volunteers 
146, 
147
. 
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HRM studies performed during the post-prandial period could be of interest for identification of 
pathophysiological mechanisms in GERD
148, 149
, particularly reflux episodes that tend to be post-prandial. 
A reflux episode may occur during a TLESR, from low LES pressure, or in conjunction with rumination 
(increased gastric pressure with or without decreased thoracic pressure) or supragastric belching (air 
swallowing to initiate belching)
148
. Post-prandial HRM has also been used to evaluate the efficacy of 
drugs targeted to TLESRs, rumination, and supragastric belching
150, 151
. However, several limitations 
exist, including lack of normative postprandial HRM data, difficulties with standardization of the test 
meal, and unclear optimal duration of the recording period.  
 
Classification of Motility Findings in GERD 
The most common motility pattern in GERD is a normal study. However, either the EGJ or the 
esophageal body, or both can be abnormal. The EGJ can be hypotensive, with or without a hiatus hernia. 
Peristalsis can be fragmented, ineffective or absent, with or without contraction reserve. The Lyon 
Consensus endorses the hierarchical classification of motility findings in GERD first evaluating EGJ 
morphology and function with LES-CD separation and the EGJ-CI, secondly characterizing the integrity 
of peristalsis as normal, weak, fragmented or absent, and third, evaluating for contraction reserve
7
 (Table 
2). This classification is intended to be used in conjunction with the Chicago Classification. 
 
ADVANCES SINCE THE PORTO CONSENSUS 
The Lyon Consensus builds on the Porto Consensus of 2002
46
, providing recommendations for 
the use and interpretation of reflux testing techniques in 2017 including esophageal HRM and baseline 
impedance measurement that were not widely available in 2002 (Table 3). The primary indication for 
reflux testing is in distinguishing among patients with pathologic reflux burden, reflux mediated 
hypersensitivity, and functional syndromes (Table 4)
152
. The Lyon Consensus attempts to augment this 
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approach by stratifying the significance of findings into those that are conclusive of pathologic GERD, as 
opposed to suggestive of the diagnosis (Figure 3). The Lyon Consensus also proposes the concept of 
‘borderline’ or inconclusive evidence when additional evidence can sway the final judgment toward or 
away from GERD. This is an area where novel metrics and diagnostic techniques may prove helpful. 
Conditions that can mimic GERD, such as achalasia, supragastric belching and rumination syndrome 
need to be excluded with appropriate testing. 
 
Optimization of GERD Testing 
GERD symptoms are diverse, response to treatment is variable, pathogenesis is heterogeneous, 
and mechanistic phenotypes are heavily influenced by hypersensitivity and hypervigilance.  Because 
simple algorithms starting with a PPI trial do not consider these complex phenotypes of GERD, they often 
lead to inappropriate PPI utilization, delayed diagnosis, and inaccurate diagnoses 
153
. The Lyon 
Consensus opines that the optimal initial testing for PPI non-responders with no prior endoscopic or pH-
metry demonstration of GERD is pH- or pH-impedance monitoring done withholding antisecretory 
therapy. A key potential outcome of that testing is to rule out GERD and to redirect management toward 
weaning off PPIs, using neuromodulators and/or cognitive behavioral therapy as appropriate. In contrast, 
optimal testing in poorly responsive patients with a prior demonstration of GERD is the combination of 
EGD, HRM, and pH-impedance monitoring done on twice-daily PPI therapy. This combination of tests 
serves both to redirect therapy toward alternative diagnoses and to mechanistically subtype patients in 
terms of poor clearance, excessive reflux episodes and hypersensitivity (Table 4), each of which can 
trigger specific management options. The precise roles of baseline impedance, PSPW index and 
provocative maneuvers on HRM remain to be clarified with future research. 
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Outcome Measures in GERD 
The optimal use of diagnostic testing may translate into better therapeutic outcomes, but 
appropriate outcome measures are necessary to properly evaluate that improvement. Esophagitis healing 
is a common measure for therapeutic trials, but visible esophagitis is rare in patients with refractory 
GERD symptoms 
25
, and the objective of the evaluation is to determine if refractory symptoms are 
attributable to GERD or not. Hence, potentially relevant outcome measures are symptom description
154
, 
symptom questionnaires
155
, pictograms with visual depictions of symptoms
156, 157
, and ambulatory reflux 
monitoring with analysis of reflux-symptom association
75, 158
. Outcome measures typically utilized in 
GERD therapeutic trials have included individual symptom assessment with Likert or visual analog 
scales
159
, global outcome evaluations on Likert scales
160
, adequate vs. inadequate relief, disease-specific 
questionnaires
161
, and quality of life questionnaires. Looking to the future, regulatory agencies have 
stipulated that validated patient reported outcome questionnaires (PROs) and quality of life questionnaires 
will be requisite in future therapeutic trials.  Such PROs require a fastidious approach that includes item 
generation, testing for reliability, responsiveness, validity and interpretability, and finally, cross-cultural 
adaptation when applicable, for each diagnostic category
162
.  
 
CONCLUSIONS AND FUTURE DIRECTION 
GERD is a complex disease with a heterogeneous symptom profile and a multifaceted pathogenic 
basis that defies a simple diagnostic algorithm or categorical classification.  The Lyon Consensus defines 
parameters on esophageal testing that conclusively establish the presence of GERD and characteristics 
that rule out GERD. Additional evidence from reflux-symptom association, motor findings on HRM, 
novel metrics from pH-impedance monitoring, baseline mucosal impedance and PPI response 
complement esophageal testing when pH-metry is borderline or inconclusive. While acknowledging the 
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limitations of currently available esophageal testing in GERD, the Lyon Consensus proposes this model 
as a guide to direct management. 
The future approach to phenotyping GERD patients should focus on assessing important 
physiologic biomarkers and PROs to categorize patients based on the severity of refluxate exposure, 
mechanism of reflux, effectors of clearance, and underlying EGJ pathophysiology (Table 4), while 
recognizing that no single approach is perfect. Novel metrics assessing tissue resistance, esophageal 
clearance, peripheral and central neural integration, and psychometrics will allow for a tailored 
therapeutic approach including pharmacologic treatments, surgical/endoscopic interventions, and 
behavioral strategies targeting the underlying defect(s) in the antireflux barrier, esophageal clearance, 
visceral sensitivity, and cognitive response to reflux. As newer metrics emerge, the Lyon Consensus plans 
future meetings to update and adapt the Consensus conclusions. Collaboration between high volume 
medical centers involved in GERD testing has opened possibilities for more robust normative data and for 
validation of conclusions and recommendations from the Lyon Consensus. As the GERD diagnostic 
paradigm evolves, utilizing diagnostic testing to define a precision approach tailored to the individual 
patient becomes possible. The goals of evaluation should therefore transition toward defining GERD 
phenotypes to facilitate tailored treatment. 
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Table 1 Studies that have compared the EGJ-CI among patient and control populations. Values reported at 
median (IQR). 
Study Subject groups EGJ-CI 
(mmHgcm) 
Notes 
Nicodème 2014111 Controls (n=75) 
GERD (n=7) 
Functional (n=45) 
39 [25-55] 
18* [8-30] 
27 [17-69] 
GERD had +++ abnormal pH-
impedance studies vs partial + 
or - for functional 
Tolone 2015112 Functional (n=39) 
GERD (n=91) 
22 [10-41] 
11* [3-21] 
GERD or functional by 
endoscopy and pH-impedance 
testing 
Jasper 2016113 Controls (n=65) 
GERD (n=116) 
63 [50-90] 
50* [28-70] 
GERD by pH-metry 
Wang 2016114 Controls (n=21) 
GERD (n=68) 
35 [26-58] 
30* [15-53] 
GERD patients underwent 
fundoplication 
Xie 2017115 Controls (n=21) 
Esophagitis (n=39) 
NERD (n=38) 
Hypersensitive (n=21) 
63 [38-83] 
22* [20-31] 
26* [15-38] 
30* [19-44] 
Patients differentiated by pH-
impedance and symptom 
correlation 
Ham 2017109 Controls (n=23) 
Esophagitis (n=25) 
NERD (n=16) 
Non-GERD ((n=91) 
67 [27-79] 
28* [4-63] 
26* [15-32] 
51 [3-153] 
Non-GERD patients had 
negative pH-impedance studies 
*p<0.05 vs controls or comparator 
Methods of EGJ-CI computation were not uniform between these studies, and this might explain 
differences in calculated thresholds. NERD: non-erosive reflux disease 
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Table 2. Classification of motor function in GERD using esophageal high-resolution manometry 
 Metrics Description 
EGJ barrier function 
Morphology Separation between LES and 
crural diaphragm (CD) 
Type 1: superimposed LES and CD 
Type 2: axially separated LES and CD 
pressure signals separated by less than 3 
cm 
Type 3a: ≥3 cm separation between the 
LES and CD pressure signatures with 
respiratory inversion point at the level of 
the CD 
Type 3b: ≥3 cm separation between the 
LES and CD pressure signatures with 
respiratory inversion point at the level of 
the LES 
Vigor EGJ-CI (mmHg●cm) 
 
DCI box set to encompass the LES and 
CD over a period of three complete 
respiratory cycles above a threshold 
pressure of the gastric baseline 
 
Esophageal body motor function 
 
 
 
 
 
 
 
Distal contractile integral, DCI 
(mmHg●cm●s) 
 
Defect (measure at 20-mmHg 
isobaric contour) 
Intact: ≥ 50% of contractions with DCI > 
450 mmHg●cm●s and no defect 
 
Fragmented: ≥ 50% of contractions with 
DCI > 450 mmHg●cm●s and defect > 5 
cm 
 
Ineffective esophageal motility: ≥ 50% of 
contractions with DCI < 450 
mmHg●cm●s 
 
Absent peristalsis: 100% of contractions 
with DCI < 100 mmHg●cm●s 
Provocative tests 
MRS (5 liquid swallows 
- 2ml each - taken less 
than 4 seconds apart) 
 
Contractile response 
 
Failure of contractile response 
Post MRS DCI augmentation 
 
Absent post MRS contraction 
RDC (free water 
drinking of 200ml of 
water within 30 
seconds) 
 
Panesophageal pressurization 
 
LES relaxation 
 
Effective post RDC 
contraction 
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Table 3: Comparison of the Porto and the Lyon consensus conclusions. 
Porto Consensus Lyon consensus 
 
No discussion of endoscopy Conclusive endoscopic criteria for GERD 
- LA Grade C or D esophagitis 
- Biopsy-proven Barrett’s esophagus 
- Peptic stricture 
 
Esophageal impedance monitoring is the only 
recording method that can achieve high 
sensitivity for detection of all types of reflux 
episodes while pH monitoring is required for 
characterization of reflux acidity. However, the 
role of impedance monitoring in the management 
of patients with GERD still needs to be defined. 
pH-impedance monitoring is the gold standard 
for detection and characterization of reflux 
episodes but is expensive, not widely available 
and interpretation is time consuming. 
 
When reflux monitoring is indicated on PPI, pH-
impedance should be performed. 
When reflux monitoring is indicated off PPI, the 
choice between catheter based pH-monitoring, 
wireless pH monitoring and pH-impedance 
monitoring is dependent of cost and availability. 
 
No discussion of the conditions (off or on PPI) to 
perform reflux testing 
Reflux monitoring is recommended off PPI in 
instances of “unproven” GERD and on PPI in 
instances of “proven GERD” (previous LA grade 
C or D esophagitis, biopsy proven Barrett’s 
esophagus, peptic stricture or AET off PPI > 6%) 
 
No discussion of normal values  An AET < 4% is normal and an AET > 6% is 
abnormal (whatever the type of reflux monitoring 
and whether the study was performed off or on 
PPI) 
 
No discussion of normal values Reflux episodes > 80 / 24 hours is abnormal and 
< 40 is physiologic on pH-impedance performed 
off or on PPI. Number of reflux episodes is an 
adjunctive metric to be utilized when AET is 
borderline or inconclusive 
 
Basal intraluminal impedance is abnormally low 
in patients with esophageal mucosal 
abnormalities such as Barrett’s esophagus or 
esophagitis. 
Measurement of baseline mucosal impedance 
(using either through the scope device or MNBI 
during ambulatory pH-impedance monitoring) is 
an adjunctive metric for the diagnosis of GERD 
 
No discussion of reflux-symptom association A combination of a positive SI and positive SAP 
provides the best evidence of clinically relevant 
association between reflux episodes and 
symptoms. 
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Using manometry, common cavities occur during 
a higher proportion of reflux episodes in neonates 
and infants than in adults 
 
No discussion of esophageal motor function in 
GERD 
Esophageal high-resolution manometry is not 
useful for the direct diagnosis of GERD but can 
provide adjunctive information 
- to assess EGJ barrier function including its 
morphology (type I to III) and its vigor (using 
EGJ-CI) 
- to evaluate esophageal body motor function 
(intact, ineffective, fragmented or absent 
contractility) that correlates with esophageal 
reflux burden 
 
Adjunctive tests should be included in the HRM 
protocol  
- to evaluate the contractile response (multiple 
rapid swallow) 
- to evaluate EGJ obstruction (rapid drink 
challenge test) 
 
Bilitec™ is a monitoring system that can detect 
duodeno-gastro-oesophageal reflux (DGOR) by 
utilizing the optical properties of bilirubin 
 
Bilitec™ is no longer considered a reliable 
diagnostic tool for GERD and was not discussed 
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Table 4. GERD phenotypes predicting abnormal reflux burden from clinical evaluation and esophageal testing 
 Pathologic GERD  
 High likelihood Intermediate likelihood Low likelihood Modifiers 
CLINICAL PHENOTYPES 
Symptoms Heartburn, acid regurgitation Chest pain Cough, laryngeal symptoms Hypersensitivity and 
hypervigilance 
Endoscopy High-grade esophagitis, 
Barrett’s mucosa, peptic 
stricture 
Low-grade esophagitis, 
Normal exam on PPI 
therapy 
 Hiatus hernia, ongoing PPI 
therapy 
ROME IV NERD (abnormal pH 
metry)* 
Symptom response to 
PPI therapy 
Reflux hypersensitivity 
functional heartburn, 
functional chest pain 
Hypersensitivity and 
hypervigilance 
Lyon Consensus* Conclusive evidence of 
GERD 
Borderline or 
inconclusive evidence 
Physiologic reflux 
parameters 
Novel metrics 
Motor classification 
MECHANISTIC PHENOTYPES 
Pattern of reflux Increased acid exposure 
± increased numbers of 
reflux episodes* 
Borderline acid exposure 
± borderline numbers of 
reflux episodes* 
Normal reflux metrics pH of refluxate, baseline 
impedance, hypochlorhydria, 
achlorhydria 
Mechanism of reflux TLESR 
Hypotensive EGJ 
Abnormal EGJ morphology 
Supragastric belch 
Rumination 
Normal EGJ morphology 
and function 
Obesity, increased 
abdominal girth 
Clearance of refluxate Absent contractility 
Hiatus hernia 
Minor motor disorder ± 
contraction reserve 
Normal peristalsis Xerostomia, baseline 
impedance, PSPW index, 
motor classification 
Cognition, perception of 
sensation 
Appropriate symptom 
perception, symptom reflux 
association 
Increased perception  Visceral hypersensitivity, 
hypervigilance 
 
Anxiety, depression 
Panic disorder 
*as described by the Lyon Consensus, Figure 3 
NERD: nonerosive reflux disease; EGD: esophagogastroduodenoscopy; TLESR: transient lower esophageal sphincter relaxation; EGJ: 
esophagogastric junction; PSPW: post-reflux swallow induced peristaltic wave 
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FIGURE LEGENDS 
Figure 1. Esophagogastric junction morphology as depicted in HRM.  With type 1 morphology the crural 
diaphragm (CD) component, evident during inspiration (I), is completely superimposed of the lower 
esophageal sphincter (LES) component such that the magnitude of the actual LES pressure is not 
discernible.  With Type 2 morphology, there is partial separation of the LES and CD constituents, but the 
respiratory inversion point (RIP) remains at the level of the CD, evident by the decrease observed in the 
LES pressure band during inspiration.  Other characteristics of Type 2 morphology are that the LES-CD 
separation is <3 cm and that the pressure trough between the LES and CD is greater than intragastric 
pressure.  With Type 3 morphology, there is ≥3 cm separation between the LES and CD and the pressure 
trough between the two is equal to intragastric pressure during expiration (E).  However, the RIP remains 
at the level of the CD in type 3a and elevated to the level of the LES pressure band with 3b.  This is 
evident by the decreases in LES pressure during inspiration in IIIa and increases in LES pressure during 
inspiration in 3b. 
Figure 2. High-resolution manometry metrics used in the motor classification of GERD. The 
esophagogastric junction contractile integral (EGJ-CI) measures vigor of the EGJ barrier using a software 
tool that encompasses length and vigor of the EGJ above the gastric baseline. The measurement is made 
over three respiratory cycles during quiet rest, and corrected for duration of respiration. The distal 
contractile integral (DCI) measures vigor of smooth muscle contraction taking length, duration and 
amplitude of contraction into consideration. Following a series of repetitive swallows (multiple rapid 
swallows, MRS), DCI augments higher than mean DCI from single swallows when there is contraction 
reserve. 
Figure 3. Interpretation of esophageal test results in the context of GERD. Any one conclusive finding 
provides strong evidence for the presence of GERD. While a normal EGD does not exclude GERD on its 
own, this provides strong evidence against GERD when combined with acid exposure time (AET) <4% 
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and <40 reflux episodes on pH-impedance monitoring off PPI therapy. When evidence is inconclusive or 
borderline, adjunctive or supportive findings can add confidence to the presence or absence of GERD. 
Histopathology as an adjunctive measure requires a dedicated scoring system (incorporating papillary 
elongation, basal cell hyperplasia, dilated intercellular spaces (DIS), intraepithelial inflammatory cells, 
necrosis and erosions) or evidence of DIS on electron microscopy. However, adjunctive findings, 
particularly histopathology and motor findings in isolation, are not enough to diagnose GERD. HRM: 
high-resolution manometry; AET: acid exposure time; MNBI: mean nocturnal baseline impedance; 
PSPWI index: post-reflux swallow-induced peristaltic wave index; EGJ: esophagogastric junction. 
